Humanetics

42 articles about Humanetics

• Humanetics Corporation to Present at Investor and Partnering Conferences

  2/7/2024

  Humanetics Corporation has announced that it will present and participate in several investor and partnering conferences in February.

• Major General (Ret.) Barbara R. Holcomb Joins Board at Humanetics

  12/12/2023

  Humanetics Corporation, a clinical-stage specialty pharmaceutical company pioneering radiation countermeasures, adjunctive oncology therapies, and pulmonary protective therapies, has announced the addition of Major General Barbara R. Holcomb, RN, BSN, MSN to its board of directors.

• Humanetics Corporation Appoints Dr. Colin Chinn as Chief Medical Officer

  11/14/2023

  Humanetics Corporation, a leading innovator in medical countermeasures, is thrilled to announce the appointment of retired Rear Admiral Dr. Colin Chinn as its new Chief Medical Officer.

• Humanetics Biomed expands its outsourced manufacturing capabilities to new markets

  5/19/2023

  Humanetics Biomed is a Contract Development Manufacturing Organisation that combines the best biomedical technologies from Humanetics; with the technical engineering expertise for research and development of precision lasered components and subcomponents for medical devices.

• Humanetics Corporation Presents at the 68th Annual International Radiation Research Society Meeting

  10/25/2022

  Humanetics Corporation (Humanetics) presented data related to its new drug candidate, BIO 300, at the 68th Annual International Radiation Research Society Meeting, October 16-19, 2022.

• Humanetics Receives FDA Clearance to Begin Studies in Second Oncology Indication

  10/5/2022

  FDA clears way for human trials of BIO 300 to mitigate erectile dysfunction in men undergoing radiation treatment for prostate cancer.

• Thomas F. Jasper Joins Board at Humanetics

  9/22/2022

  Humanetics Corporation, a clinical-stage specialty pharmaceutical company pioneering radiation countermeasures, adjunctive oncology therapies, and pulmonary protective therapies for COVID-19, has announced the addition of Minneapolis businessperson Tom Jasper to its board of directors.

• Jake R. Nunn Joins Board at Humanetics

  8/10/2022

  Humanetics Corporation, a clinical-stage specialty pharmaceutical company pioneering radiation countermeasures, adjunctive oncology therapies, and pulmonary protective therapies for COVID-19, has announced the addition of renowned venture capitalist and life science industry expert Jake R. Nunn to the Company’s Board of Directors.

• BIO 300 Pharmacokinetics Studies Published

  7/27/2022

  A recently published paper in Radiation Research, the official journal of the Radiation Research Society, details the results from a series of pharmacokinetics studies conducted with Humanetics Corporation’s new radioprotective drug, BIO 300.

• U.S. Department of Defense Awards $5.1 Million to Humanetics Corporation for Continued Development of Radiation Countermeasure

  6/21/2022

  Minneapolis-based Humanetics Corporation has entered into a new $5.1 million cooperative research agreement with the U.S. Department of Defense to continue advanced development of BIO 300, a medical countermeasure to protect military personnel and first responders from the harm caused by radiation exposure.

• Humanetics Acquires mg-sensor to Advance Its Safety, Digital and Sensor Vision

  6/21/2022

  Humanetics announced that mg-sensor GmbH, specialists in the design and development of high-quality sensors, data acquisition and calibration services, is officially joining the Humanetics group.

• Humanetics Corporation Expands Long-Haul COVID-19 Trial to Additional Sites

  5/18/2022

  Humanetics Corporation has added two additional clinical sites to its long-haul COVID-19 study, which is focused on patients who were treated for severe COVID-19 and face the possible risk that their respiratory complications will lead to long-term impairment of lung function.

• Humanetics Corporation’s BIO 300 Receives Fast Track Designation from FDA

  8/24/2021

  Humanetics Corporation (Humanetics) announced today that BIO 300, a drug under development to increase survival in persons exposed to high levels of radiation, has been granted Fast Track status by the U.S. Food and Drug Administration (FDA).

• Humanetics Corporation Receives Funding From Department of Defense to Test Drug Against COVID-19

  1/26/2021

  BIO 300 will be tested as a post-infection prophylactic to mitigate pulmonary inflammation leading to COVID-19 complications

• Amit Singhi joins Humanetics Group as Chief Financial Officer (CFO)

  12/1/2020

  HUMANETICS GROUP, the global safety, sensor and precision engineering business, announced that Amit Singhi has joined the Humanetics Group as Chief Financial Officer reporting to Chris O’Connor, President and CEO.

• Humanetics Corporation Presents at the Annual Radiation Research Society Meeting

  10/20/2020

  Humanetics Corporation (Humanetics) presented at the 2020 Annual Meeting of the Radiation Research Society (RRS), held virtually October 18 th through the 21 st . Artur Serebrenik, Ph.D., of Humanetics presented data related to the Company’s medical countermeasure for radiation exposure, BIO 300 Oral Powder. The data describe the developme

• Former Surgeon General of the U.S. Navy, Vice Admiral Matthew L. Nathan, M.D., Joins Board of Directors at Minneapolis-based Humanetics

  9/15/2020

  Humanetics Corporation has elected Vice Admiral Matthew L. Nathan, M.D. to its Board of Directors. Dr. Nathan has held a seat on the Company’s Medical Advisory board since 2017.

• Humanetics Corporation to Present at the Annual Meeting of the American Society for Radiation Oncology

  10/23/2018

  Humanetics has been invited to present at the annual meeting of the American Society for Radiation Oncology (ASTRO) being held October 21st through the 24th in San Antonio, Texas.

• Humanetics Awarded Patent for Oral Drug to Protect Warfighters and First Responders from Radiation Exposure

  7/17/2018

  Humanetics Corporation (Humanetics) has been awarded a United States patent for its lead drug candidate, BIO 300.

• Humanetics Corporation Awarded Federal Grant for Development of New Radiation Countermeasure to Protect the Lungs

  4/12/2018

  The National Institute of Allergy and Infectious Diseases Radiation Nuclear Countermeasures Program awarded the contract